Tolcapone in the management of Parkinson’s disease

Bibliography

• TANNER CM: Epidemiology of Parkinson’s disease. Neurol. Clin. (1992) 10:317-329.
   PubMedGoogle Scholar
• HORNYKIEWICZ O: Biochemical aspects of Parkinson’s disease. Neurology (1998) 51:S2-S9.
   PubMed Web of Science ®Google Scholar
• GASSER T: Genetics of Parkinson’s disease. Curr. Opin. Neurol. (2005) 18:363-369.
   PubMed Web of Science ®Google Scholar
• MARSDEN CD: Parkinson’s disease. J. Neurol. Neurosurg. Psychiatry (1994) 57:672-681.
   Google Scholar
• VAN GERPEN JA, KUMAR N, BOWER JH, WEIGAND S: Levodopa-associated dyskinesia risk among Parkinson’s disease patients in Olmsted county, Minnesota, 1976 – 1990. Arch. Neurol. (2006) 63:205-209.
   PubMedGoogle Scholar
• WATERS C: Other pharmacological treatments for motor complications and dyskinesias. Mov. Disord. (2005) 20(Suppl. 11):S38-S44.
   PubMed Web of Science ®Google Scholar
• KAAKKOLA S: Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson’s disease. Drugs (2000) 59:1233-1250.
   PubMed Web of Science ®Google Scholar
• MANNISTO PT: Clinical potential of catechol-O-methyl-transferase (COMT) inhibitors as adjuvants in Parkinson’s disease. CNS Drugs (1994) 1:172-179.
   PubMed Web of Science ®Google Scholar
• KAAKKOLA S, GORDIN A, MANNISTO PT: General properties and clinical possibilities of new selective inhibitors of catechol-O-methyltransferase. Gen. Pharmacol. (1994) 25:813-824.
   PubMedGoogle Scholar
• MANNISTO PT, KAAKKOLA S: Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson’s disease. Pharmacol. Toxicol. (1990) 66:317-323.
   PubMedGoogle Scholar
• ZURCHER G, DINGEMANSE J, DA PRADA M: Potent COMT inhibition by Ro 40-7592 in the periphery and in the brain. Adv. Neurol. (1993) 60:641-647.
   PubMedGoogle Scholar
• CERAVOLO R, PICCINI P, BAILEY DL, JORGA KM, BRYSON H, BROOKS DJ: 18F-Dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson’s disease. Synapse (2002) 43:201-207.
   PubMed Web of Science ®Google Scholar
• MULLER T, KUHN W. Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkisnon’s disease patients. Eur. J. Clin. Pharmacol. (2006) 62:447-450.
   PubMedGoogle Scholar
• DE SANTI C, GIULIANOTTI PC, PIETRABISSA A, MOSCA F, PACIFICI GM: Catechol-O-methyltransferase: variation in enzyme activity and inhibition by entacapone and tolcapone. Eur. J. Clin. Pharmacol. (1998) 54:215-219.
   PubMed Web of Science ®Google Scholar
• DINGEMANSE J, JORGA K, ZURCHER G et al.: Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects. Eur. J. Clin. Pharmacol. (1995) 50:47-55.
   Google Scholar
• DINGEMANSE J, JORGA K, SCHMITT M et al.: Integrated pharmacokinetic and pharmacodynamics of the novel catechol-O-methyl-transferase inhibitor tolcapone during first administration to humans. Clin. Pharmacol. Ther. (1995) 57:508-517.
   PubMed Web of Science ®Google Scholar
• DINGEMANSE J, JORGA K, ZURCHER G et al.: Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br. J. Clin. Pharmacol. (1995) 40:253-262.
   PubMed Web of Science ®Google Scholar
• JORGA KM, KROODSMA JM, FOTTELER B et al.: Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites. Clin. Pharmacol. Ther. (1998) 63:646-654.
   PubMed Web of Science ®Google Scholar
• JORGA KM, SEDEK G, FOTTELER B et al.: Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly. Clin. Pharmacol. Ther. (1997) 62:300-310.
   PubMed Web of Science ®Google Scholar
• SEDEK G, JORGA K, SCHMITT M et al.: Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers. Clin. Neuropharmacol. (1997) 20:531-541.
   PubMed Web of Science ®Google Scholar
• LIMOUSIN P, POLLAK P, PFEFEN JP et al.: Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, in Parkinson’s disease. Clin. Neuropharmacol. (1995) 18:258-265.
   PubMedGoogle Scholar
• NAPOLITANO A, DEL DOTTO P, PETROZZI L et al.: Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson’s disease. Clin. Neuropharmacol. (1999) 22:24-29.
   PubMed Web of Science ®Google Scholar
• DAVIS TL, ROZNOSKI M, BURNS RS: Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegiline. Clin. Neuropharmacol. (1995) 18:333-337.
   PubMed Web of Science ®Google Scholar
• YAMAMOTO M, YOKOCHI M, KUNO S et al.: Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson’s disease. J. Neural. Transm. (1997) 104:229-236.
   PubMedGoogle Scholar
• BAAS H, BEISKE AG, GHIKA J et al.: Catechol-O-methyl-transferase inhibition with tolcapone reduces the ‘wearing off’ phenomenon and levodopa requirements in fluctuating parkinsonian patients. J. Neurol. Neurosurg. Psychiatry (1997) 63:421-428.
   Google Scholar
• RAJPUT AH, MARTIN W, SAINT-HILAIRE M-H et al.: Tolcapone improves motor function in parkinsonian patients with the ‘wearing-off’ phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology (1997) 49:1066-1071.
   PubMed Web of Science ®Google Scholar
• WATERS, CH, KURTH M, BAILEY P et al.: Tolcapone in stable Parkinson’s disease: efficacy and safety of long-term treatment. Neurology (1997) 49:665-671.
   PubMed Web of Science ®Google Scholar
• DUPONT E, BURGUNDER JM, FINDLEY LJ et al.: Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson’s disease Study Group II (TIPS II). Mov. Disord. (1997) 12:928-934.
   PubMed Web of Science ®Google Scholar
• SUCHOWERSKY O, BAILEY P, POURCHAR E et al.: Comparison of two dosages of tolcapone added to levodopa in nonfluctuating patients with PD. Clin. Neuropharmacol. (2001) 24:214-220.
   PubMedGoogle Scholar
• WIDNELL K: Pathophysiology of motor fluctuations in Parkinson’s disease. Mov. Disord. (2005) 20:S17-S22.
   PubMedGoogle Scholar
• JORGA K, FOTTELER B, SCHMITT M et al.: The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations. Eur. Neurol. (1997) 38:59-67.
   PubMedGoogle Scholar
• JORGA K, FOTTELER B, SEDEK G et al.: The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation. J. Neurol. (1998) 245:223-230.
   PubMedGoogle Scholar
• JORGA KM: COMT inhibitors: pharmacokinetic and pharmacodynamic comparisons. Clin. Neuropharmacol. (1998) 21:S9-S16.
   Google Scholar
• FACTOR SA, MOLHO ES, FEUSTEL PJ et al.: Long-term comparative experience with tolcapone and entacapone in advanced Parkinson’s disease. Clin. Neuropharmacol. (2001) 5:295-299.
   Google Scholar
• ONOFRJ M, THOMAS A, IACONO D et al.: Switch-over from tolcapone to entacapone in severe Parkinson’s disease patients. Eur. Neurol. (2001) 46:11-16.
   PubMed Web of Science ®Google Scholar
• AGID Y, OERTEL W, FACTOR S: The Entacapone to Tolcapone Switch Study Investigators: entacapone to tolcapone switch: multicenter double-blind, randomized, active-controlled trial in advanced Parkinson’s disease. Mov. Disord. (2005) 20(Suppl. 94):XXX-XXX.
   Google Scholar
• TOLCAPONE STUDY GROUP: Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated Parkinsonian patients. Mov. Disord. (1999) 14:38-44.
   PubMed Web of Science ®Google Scholar
• KOLLER W, LEES A, DODER M, HELY M and the TOLCAPONE/PERGOLIDE STUDY GROUP: Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson’s disease patients with motor fluctuations. Mov. Disord. (2001) 16:858-866.
   PubMed Web of Science ®Google Scholar
• ADLER CH, SINGER C, O’BRIEN C et al.: Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson’s disease treated with levodopa-carbidopa. Arch. Neurol. (1998) 55:1089-1095.
   PubMedGoogle Scholar
• ASSAL F, SPAHR L, HADENGUE A et al.: Tolcapone and fulminant hepatitis. Lancet (1998) 352:958.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: New warnings for Parkinson’s drug Tasmar. Rockville, MD: Food and drug administration. (1998) Talk paper T98-T81.
   Google Scholar
• OLANOW CW and the TASMAR ADVISORY PANEL: Tolcapone and hepatotoxic effects. Arch. Neurol. (2000) 57:263-267.
   PubMed Web of Science ®Google Scholar
• KEATING GM, LYSENG-WILLIAMSON KA: Tolcapone: a review of its use in the management of Parkinson’s disease. CNS Drugs (2005) 19:165-184.
   PubMed Web of Science ®Google Scholar
• ACUNA G, FOERNZLER D, LEONG D et al.: Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity. Pharmacogenomics J. (2002) 2:327-334.
   PubMedGoogle Scholar
• MARTIGNONI M, COSENTINO M, FERRARI G et al.: Two patients with COMT inhibitor–induced hepatic dysfunction and UGT1A9 genetic polymorphism. Neurology (2005) 65:1820-1822.
   PubMed Web of Science ®Google Scholar